Navigation Links
NeurogesX Receives European Commission Approval for Qutenza(TM)
Date:5/21/2009

Approved for peripheral neuropathic pain in non-diabetic adults

SAN MATEO, Calif., May 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Commission has formally granted marketing authorization of Qutenza(TM) 179 mg cutaneous patch (formerly NGX-4010) for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. Qutenza can only be obtained with a prescription. The centralized marketing authorization allows Qutenza to be marketed in all 27 countries of the European Union.

The approval of Qutenza follows a positive opinion recommending approval from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) on March 19, 2009. Qutenza, a cutaneous (dermal) patch, is designed to locally deliver a high-concentration (8%) of the active substance capsaicin and to provide sustained relief from peripheral neuropathic pain. Following application to the painful areas on the skin, Qutenza is allowed to remain in place for 30 minutes for the feet (e.g., HIV-associated neuropathy) and 60 minutes for other locations (e.g., postherpetic neuralgia). Qutenza is not indicated for adults who have diabetes as there is only limited experience with Qutenza in patients with Painful Diabetic Neuropathy (PDN), and repeated treatments with Qutenza in patients with PDN have not been studied.

NeurogesX anticipates that Qutenza will be marketed in the European Union through a commercial partner.

Anthony DiTonno, President and CEO, commented, "The European approval of Qutenza represents a major milestone for NeurogesX. It marks the culmination of years of developm
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... July 21, 2015 ... the addition of the "Analysis of the ... their offering. Globally, flow cytometry remains ... cell proliferation, cancer, and stem cells. But the ... primarily because of demand from underdeveloped nations to ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... VetStem ... a live stem cell credentialing course to local area veterinarians. , The tour and ... approved CE units at no charge) at VetStem’s Poway facility. Staff members are welcome ...
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2
... Neuftec,Limited, the proprietor of the original nano-particulate ... claim against Oxonica Energy,Limited, a wholly owned subsidiary ... in the High Court of Justice, has commented ... by Dr Matthews,(CEO) on 19 June 2008., ...
... have invented an affordable technique that uses lasers and ... needed for new generations of microchips. , The ... times narrower than a human hair, may enable the ... applications in medicine, optical communications, computing and sensor technologies. ...
... June 18 ,Exelixis, Inc. (Nasdaq: EXEL ) announced ... officer at Exelixis, will present at the,Piper Jaffray Europe ... time on Wednesday, June 25, 2008. Mr. Karbe will ... The presentation will be webcast and may be ...
Cached Biology Technology:Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 2Trap and zap: Harnessing the power of light to pattern surfaces on the nanoscale 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... Scientists at Albert Einstein College of Medicine of ... (GCE) grants from the Bill & Melinda Gates Foundation ... grant recipients are Arturo Casadevall , M.D., Ph.D., who is ... Ekaterina Dadachova , Ph.D., and Joan Berman , Ph.D., for ...
... of Colorado Boulder has been awarded $9.2 million over five years ... coli to produce biofuels such as gasoline. "This ... for the past decade to the next level," said team leader ... or RASEI. "In this project, we will develop technologies that are ...
... confirms that lions are rapidly and literally losing ground ... growth and subsequent, massive land-use conversion. Representing the most ... savannah habitat to date, the report maintains that the ... in Africa a reduction that has devastated lion ...
Cached Biology News:Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 2Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB 3CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2New study reveals lions are rapidly losing ground in Africa 2New study reveals lions are rapidly losing ground in Africa 3
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Apoptosis Detection Systems and Reagents...
...
...
Biology Products: